Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study
Lin Yang(Fujian Medical University), Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Yanhong Deng(Sun Yat-sen University), Suxia Luo(Henan Cancer Hospital), Yi Ba(Tianjin Medical University Cancer Institute and Hospital), Hong Zong(First Affiliated Hospital of Zhengzhou University), Yajie Gao(Dalian Medical University), Guohua Yu(Qingdao University), Jianfeng Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Liangzhi Xie(Sinocelltech Group (China)), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Ying Cheng(Jilin Province Tumor Hospital), Lingjun Zhu(Henan University), Wenlin Gai(Sinocelltech Group (China)), Yuxian Bai(Harbin Medical University), Wěi Li(Shougang (China)), Yan Wang(Sinocelltech Group (China)), Wen Zhang(Xidian University), Tianshu Liu(Sun Yat-sen University), Kangsheng Gu(Anhui Medical University), Jianhua Shi(Linyi People's Hospital), Guanghai Dai(Chinese PLA General Hospital), Xianli Yin(Central South University), Nanfeng Fan(Fujian Medical University), Peng Meng(Burning Rock Biotech (China)), Mayinuer Aili(Xinjiang Medical University), Peiguo Cao(Central South University)
Cited by 10
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
HIF-1α pathway: role, regulation and intervention for cancer therapy
|Acta Pharmaceutica Sinica B|2015|1.9k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k